Recent advancements in the development of drugs for IBD include drugs targeting TNF and new candidate drugs, such as antibodies against IL-6 [50] and IL-12/23 [51–53], small molecules including Janus kinase inhibitors [54], antisense oligonucleotides against SMAD7 mRNA [55], and inhibitors of leukocyte trafficking to intestinal sites of inflammation [56, 57]. This evidence concerns the gene TNF and inflammatory bowel disease.